Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GLS | O94925 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350083 | 0.90 | HTT (0.66) | HTTHSD17B10POLBF2ALDH1A1 | |
| SCHEMBL8350469 | 0.89 | HTT (0.64) | HTTHSD17B10POLBF2ALDH1A1 | |
| SCHEMBL11418576 | 0.83 | POLB (0.64) | HTTHSD17B10POLBF2ALDH1A1 | |
| SCHEMBL8358314 | 0.82 | HTT (1.00) | HTTHSD17B10POLBF2ALDH1A1 | |
| SCHEMBL20631846 | 0.81 | HSD17B10 (0.48) | HTTHSD17B10POLBALDH1A1GLS | |
| SCHEMBL2640913 | 0.78 | POLB (0.55) | HTTHSD17B10POLBF2ALDH1A1 | |
| SCHEMBL8351229 | 0.73 | GLS (0.58) | HSD17B10POLBALDH1A1GLS | |
| SCHEMBL15742353 | 0.73 | POLB (0.59) | HTTHSD17B10POLBF2ALDH1A1 | |
| SCHEMBL17446991 | 0.72 | ALDH1A1 (0.56) | HTTHSD17B10POLBALDH1A1 | |
| SCHEMBL1673188 | 0.72 | POLB (0.64) | HTTHSD17B10POLBALDH1A1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
| WO-1999031096-A1 | PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS | SHAMAN PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | HTT 4542/4885HSD17B10 2198/4885POLB 3273/4885 |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | HTT 4462/4885HSD17B10 2351/4885POLB 3169/4885 |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | HTT 2577/4885HSD17B10 3833/4885POLB 3249/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | HTT 4462/4885HSD17B10 2351/4885POLB 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.